SERO-PREVALENCE OF HEPATITIS B VIRUS INFECTION AND SERO-PROTECTION OF HEPATITIS B VACCINE AMONG CHILDREN IN JIMMA TOWN, SOUTHWEST ETHIOPIA

Authors

  • Rebie Kedir
  • Belayneh Dimah Taye
  • Tesfaye Kassa
  • Lule Teshager
  • Abraham Aseffa
  • Rowliegh Howe
  • Adane Mihiret
  • Addisu Gezie

Abstract

Background:Hepatitis B virus (HBV) is the leading cause of viral hepatitis and about 240 million people worldwide are chronic carriers. The virus isreported to be widely prevalent in Ethiopia and routine vaccination of children has been initiated in the country recently. We assessed the sero-prevalence of HBVinfection and sero-protection of HBVvaccine among children in Jimma town

Methods:A community based cross-sectional study was conducted among 900 children with 5-9 years-old betweenJune and December 2016. A simple random sampling technique was employed to recruit study participants by proportional allocation into different Kebeles of Jimma town. Data were collected using pretested questionnaire and about 3-5ml of blood sample was collected and tested for HBsAg, anti-HBc and anti-HBs using ELISA (Bio-rad, Monolisa, Lacquote, France).Data were analyzed using chi-square and logistic regression test.

Result:HBsAg and anti-HBc prevalence among all participants was3.5% and 3.8%, respectively. The prevalence of HBsAg among vaccinated and non-vaccinated was 2.1% and 7.0% whereas anti-HBc positivity was 1.1% and 6.2%, respectively. It was also found that 58.4% of vaccinated children retained a protective level of HB surface antibodies, ≥ 10 mIU/ml with the overall mean of 50 mIU/ml.

References

Ganem D, Prince AM. 2004. Hepatitis B virus infection, natural history and clinical consequences.N Engl J Med. 350:1118-1129

World Health Organization 2009. Hepatitis B vaccines.Wkly epid rec.84(40): 405–420.

Ott JJ, Stevens GA, Groeger J, Wiersma ST. 2012.Global epidemiology of hepatitis B virus infection: new etimates of age-specific HBsAg seroprevalence and endemicity. Vaccin.30: 2212-2219.

Lavanchy D. 2004.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. .J Viral Hepat. 11: 97-107.

World Health Organization 2016. Hepatitis B fact sheet, no 204 [updated July 2016]. Available from: http://www.who.int/mediacentre/factsheets/fs204/ Jul2016/en/.

Nel E, Sokol RJ , Comparcola D, Nobili V, Hardikar W, Gana JC, et al.. 2012. Viral Hepatitis in Children.JPGN. 55(5): 500-504.

Thursz M, Njie R, Lemoine M. 2012. Hepatitis: global eradication of hepatitis B feasible or fallacy? .Nat Rev Gastroenterol Hepatol. 9(9): 492-494

Abate M, Wolde T. 2016. Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, and Syphilis among Blood Donors at Jigjiga Blood Bank, Eastern Ethiopia. Ethiop J Health Scie. 26(2): 153-160.

Negero A, Sisay Z, Medhin G. 2011.Prevalence of hepatitis B surface antigen (HBsAg) among visitors of Shashemene General Hospital voluntary counseling and testing center. BMC Res Notes, 4(1): 1-5.

Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, et al. 2010.Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis.10(111): 1-7.

Tsega E, Nordenfelt E, Hansson BG, Mengesha B, Lindberg J. 1992. Chronic liver disease in Ethiopia: a clinical study with emphasis on identifying common causes. Ethiop Med. J,30(2):1-33.

Tsega E. 2000. Epidemiology, prevention and treatment of viral hepatitis with emphasis on new developments. Ethiop Med J. 38(2):131-41

Beasley RP.1983.Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet Infect Dis.2:1099-1102

Lok AS, McMahon AJ. 2007.Chronic hepatitis B. Hepatol.45: 507-39.

Recommendations of the Immunization Practices Advisory Committee (ACIP).1991. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Recomm Rep. 40(13):1–25

Romanò L, Paladini S, Zanetti AR. 2012. Twenty years of universal vaccination against hepatitis B in Italy: achievements and challenges. J.Public Health Res :18(1):126-8

Leuridan E, Damme PV. 2011. Hepatitis B and the need for a booster dose. Clin Infect Dis53:68-75

Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ. 2012. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterol.142(1):773-781.

Federal Ministery of Health 2015. Ethiopia national expanded programme on immunization, comprehensive multi-year plan 2016 - 2020.

Shiferaw F, Letebo M, Bane A. 2016. Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia.BMC Public Health16(769):1-13.

Statistical Abstracts2003. Federal Democratic Republic of Ethiopia, Central Statistical Authority of Ethiopia. The 1994 E.C (2001/2002) population and housing census of Ethiopia

Jafri W, Jafri N, Yakoob J, Islam M, Farhan S, Ahmi A, et al. 2006. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis. 6(101:1-10

Attia KA, Kissi YH, Doffou S, Bangoura D, Wilson RF, Bang US, et al. 2013. Prevalence of hepatitis B infection and factors associated in children of Ivorian HBsAg carrier subjects. Open J Gastroenterol. 23:237-40.

Ji Z, Wang T, Shao Z, Huang D, Wang A. 2014. A Population-Based Study Examining Hepatitis B Virus Infection and Immunization Rates in Northwest China. PLoS ONE9(5):1-10

Komada K, Sugiyama M, Vongphrachanh P, Vong S, Xeuatvongsa A, Khamphaphongphane B, et al. 2015. Seroprevalence of chronic hepatitis B, as determined from dried blood spots, among children and their mothers in central Lao People’s Democratic Republic: a multistage, stratified cluster sampling survey. Int. J Infect Dis.36:21-6

Ochola E, Ocama P, Orach CG, Nom P, Nankinga ZK, Kalyango JN, et al. 2013. High burden of hepatitis B infection in Northern Uganda: results of a population-based survey. BMC Public Health 13(727):1-7

Utsumi T, Lusida MI, Yano Y, Purwono PB, Amin M, Hotta SH, et al. 2014.Progress in the Control of Hepatitis B Virus Infection among Children in Indonesia. J Vaccin.5(5):1-6.

Hoz F, Perez L, Neira Md, Hall AJ. 2008. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. Int. J Infect Dis.12:183-9

Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jobarat MB, et al. 2013. Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B Vaccination in Two Gambian Villages: No Need for a Booster Dose. PLoS ONE 8(3:1-9

Attia KA, Kissi YH, Doffou S, Bangoura D, Wilson RF, Bang US, et al. 2013. Prevalence of hepatitis B infection and factors associated in children of Ivorian HBsAg carrier subjects. Open J Gastroenterol. 23:237-40.

Yonghao G, Jin X, Jun L, Pumei D, Ying Y, Xiuhong F. 2015. An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China. Int. J Infect Dis. 40:75-80

Abushady EA, Gameel MM, Klena JD, Ahmed SF, Abdel-Wahab KS, Fahmy SM. 2011. HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt. World J Hepatol. 3(6):147-56

Bhattachary H, Bhattachary D, Ghosal SR, Roy S, Sugunan AP. 2015. Status of hepatitis B infection - a decade after hepatitis B vaccination of susceptible Nicobarese, an indigenous tribe of Andaman & Nicobar (A&N) islands with high hepatitis B endemicity. Indian J Med Res.141:653-61

Al-Shamahy HA, Hanash SH, Rabbad IA, Al-Madhaji NM, Naser SM. 2011. Hepatitis B Vaccine Coverage and the Immune Response in Children under ten years old in Sana’a, Yemen. SQU Med J11:77-82

Odusanya OO, Alufohai FE, Meurice FP, Wellens R, Weil J, Ahonkhai VI. 2005. Prevalence of hepatitis B surface antigen in vaccinated children and controls in rural Nigeria. Int. J Infect Dis. 9:139-43

Peto TJ, Mendy ME, Lowe Y, Web EL, Whittle HC, Hall AJ. 2014.Efficacy and effectiveness of infant accination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. BMC Infect Dis.14(7): 1-8.

Salama II, Sami SM, Said ZNA, Al-Islam AA, El-Sayed MH, Etreby LAE, et al. 2015. Effectiveness of hepatitis B virus vaccination program in Egypt: Multicenter national project. World J Hepatol.7(22):2418-26

Xiao J, Zhang J, Wua C, Shao X, Peng G, Xi Y, et al. 2012. Impact of hepatitis B vaccination among children in Guangdong Province, China. Int. J Infect Dis. 16:e692-e6

Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. 2010. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East. Med. Health J. 16:S15-S22

Li X, Zheng Y, Liau A, Cai B, Ye D. 2012. Hepatitis B virus infections and risk factors among the general population in Anhui Province, China: an epidemiological study. BMC Public Health 12(272):1-7

Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P. 2010. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis. 10(208):1-8

Michael G, Bruce I, Bruden D, Hurlburt D, Zanis C, Thompson G, et al. 2015. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis. 1-7

Liu SL, Dong Y, Zhang L, Li MW, Lu LW.2009. Influence of HBV gene heterogeneity on the failure of immunisation with HBV vaccines in eastern China. Arch Virol 154:437-43

Lunn ER, Hoggarth BJ, Cook WJ. 2000. Prolonged hepatitis B surface antigenemia after vaccination. Pediatrics105:1-10.

Downloads

Published

2019-04-17

Issue

Section

Original Article